| __timestamp | BioMarin Pharmaceutical Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 21226345 |
| Thursday, January 1, 2015 | 152008000 | 139626 |
| Friday, January 1, 2016 | 209620000 | 93831530 |
| Sunday, January 1, 2017 | 241786000 | 79419009 |
| Monday, January 1, 2018 | 315264000 | 368673 |
| Tuesday, January 1, 2019 | 359466000 | 477121 |
| Wednesday, January 1, 2020 | 524272000 | 1895029 |
| Friday, January 1, 2021 | 470515000 | 8034589 |
| Saturday, January 1, 2022 | 483669000 | 20443000 |
| Sunday, January 1, 2023 | 577065000 | 33745000 |
In pursuit of knowledge
In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and Intra-Cellular Therapies, Inc. have showcased contrasting trajectories in their cost of revenue. BioMarin's cost of revenue has surged by approximately 345% from 2014 to 2023, reflecting its expansive growth and increased production capabilities. In contrast, Intra-Cellular Therapies, Inc. has experienced a more modest increase of around 59% over the same period, indicating a more measured approach to scaling operations.
BioMarin's peak in 2023, with costs reaching nearly 578 million, underscores its aggressive market expansion. Meanwhile, Intra-Cellular Therapies' steady rise to 33.7 million in 2023 highlights its strategic focus on niche markets. These trends offer a window into the strategic priorities and market positioning of these two industry players, providing valuable insights for investors and stakeholders alike.
Cost Insights: Breaking Down AbbVie Inc. and Intra-Cellular Therapies, Inc.'s Expenses
Analyzing Cost of Revenue: Sanofi and BioMarin Pharmaceutical Inc.
BeiGene, Ltd. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Comparing Innovation Spending: Intra-Cellular Therapies, Inc. and BioMarin Pharmaceutical Inc.
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Grifols, S.A.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Telix Pharmaceuticals Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.